Ibazocine is an analgesic that has never been marketed.

Phenobutiodil was used as the contrast medium in radiology. As a diagnostic aid in cholecystography. Conjugated phenobutiodil (Biliodyl) in the small and large bowel can be recognized by its fine, homogeneous appearance.

Propoxycarbazone-Sodium (also known as BAY MKH 6561) is asulfonylaminocarbonyltriazolinone derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as herbicide Propoxycarbazone inhibits acetolactate synthase (ALS), and has selectivity on spring, winter, and durum varieties. The spectrum of control includes several species of monocot and dicot weeds at the application rates of 30 to 45 g/ha. Bromus control is the primary target since existing herbicides have limited timing, selectivity, and use patterns which reduce usefulness. Propoxycarbazone applied postemergence between the 1- to 2-leaf stage and shoot elongation has provided economic control of the following Bromus species: B. tectorum, B. secalinus, B. mollis, B. rigidus, and B. japonicus. Side effects, and sometimes control, was also noted on Aegilops tauschii for which there is no selective control outside genetically altered wheat cultivars. Broadleaf control was obtained primarily on the mustard family, including species in the genera Sisymbrium, Brassica, Descurainia, Chorispora, Camelina, Capsella, and Thlaspi. Propoxycarbazone provides control for adequate weed spectrum, however, considerations of resistance management, difficult and diverse weed pressure, and extended growing seasons will sometimes necessitate the use of sequential herbicides or mix partners.

Xanthohumol is a prenylated flavonoid most abundant in hops. It is found in beers and refreshment drinks. It can attenuate several factors of the metabolic syndrome. It has been reported to inhibit adipogenesis or increase cell apoptosis and therefore can be used in preventing obesity. Xanthohumol inhibited angiogenesis by suppressing NF-κB activity in pancreatic cancer. Xanthohumol may represent a novel therapeutic agent for the management of pancreatic cancer. Moreover, it is in phase I clinical trials for preventing many types of cancer. It has a range of other biological properties: antiviral, antimalarial, antibacterial and as an osteoporosis preventing agent.

Nitrosourea is an anticancer agent that can cross the blood-brain barrier. Nitrosourea derrivatives represent one of the most active classes of agents in the treatment of high-grade gliomas and glioblastoma. Nitrosoureas are alkylating agents with a long history in cancer treatment. Their mechanism of action is represented by the alkylation of DNA strands, which results in DNA damage and cellular death. In particular, the chemical decomposition in aqueous solutions determines the formation of two reactive intermediates: a chloroethyldiazohydroxide and an isocyanate group. The former further decomposes into a chloroethyl carbonium ion that forms adducts and crosslinks to DNA, while isocyanates deplete glutathione, inhibit DNA repair, and alter maturation of RNA. All these chemical interactions result in cellular damage and death.

Tazadolene was developed as a novel non-opioid analgesic with antidepressant properties. Experiments on rodents have revealed that unique analgesia properties of tazadolene was due to the ability of this compound to activate both serotonergic and alpha 2 adrenergic antinociceptive systems. Information about the current use of this drug is not available.

Naxagolide (MK-458; L 647,339; (+)-PHNO) is a dopamine D2/D3-receptor agonist, which was studied for the treatment of patients with Parkinson's disease, but further study was discontinued. In addition, was discovered, that Naxagolide C-11 ([(11)C]-(+)-PHNO) was a potential radiotracer for imaging the high-affinity state of dopamine D2 receptors with positron emission tomography (PET) in human subjects. This radiotracer is a suitable for imaging the agonist binding sites (denoted D(2HIGH) and D(3)) of these receptors. PET studies in nonhuman primates documented that, in vivo, [(11)C]-(+)-PHNO displays a relative selectivity for D(3) compared with D(2HIGH) receptor sites and that the [(11)C]-(+)-PHNO signal is enriched in D(3) contribution compared with conventional ligands such as [(11)C] raclopride. Recently was published article reflects the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.

Ropitoin (TR2985) is a diphenylhydantoin derivative. It is an antiarrhythmic compound that causes a depression of the maximum upstroke velocity (used as a measure of cardiac function: an indirect index of the magnitude of the sodium current). Its effect was shown in several cardiac tissues and in guinea pig muscles and dog Purkinje fibers (myocardial cells). Ropitoin is believed to bind to the same receptor site in the sodium channel as mexiletine and quinidine. In an animal study, ropitoin was shown to be ineffective in preventing reentrant ventricular tachycardia (when the electric signal fails to die out after normal activation) or ventricular fibrillation. No information on the current use of this compound is available.

KP-1461 is a prodrug of KP-1212, an antiviral agent developed for the treatment of human immunodeficiency virus (HIV) infection. KP-1212 induces an increase in the HIV mutation rate thus leading to viral ablation.

Orpanoxin (previously known as F-776), a nonsteroidal anti-inflammatory drug that was developed as an analgesic agent. Orpanoxin is a prostaglandin synthetase inhibitor and may have a potential for the treatment of rheumatic. However, information about the current development of this drug is not available.